The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dietrich, J.
Right arrow Articles by Andersen, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dietrich, J.
Right arrow Articles by Andersen, P.
The Journal of Immunology, 2005, 174: 6332-6339.
Copyright © 2005 by The American Association of Immunologists

Exchanging ESAT6 with TB10.4 in an Ag85B Fusion Molecule-Based Tuberculosis Subunit Vaccine: Efficient Protection and ESAT6-Based Sensitive Monitoring of Vaccine Efficacy 1

Jes Dietrich2, Claus Aagaard, Robert Leah, Anja W. Olsen, Anette Stryhn, T. Mark Doherty and Peter Andersen

Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark

Previously we have shown that Ag85B-ESAT-6 is a highly efficient vaccine against tuberculosis. However, because the ESAT-6 Ag is also an extremely valuable diagnostic reagent, finding a vaccine as effective as Ag85B-ESAT-6 that does not contain ESAT-6 is a high priority. Recently, we identified a novel protein expressed by Mycobacterium tuberculosis designated TB10.4. In most infected humans, TB10.4 is strongly recognized, raising interest in TB10.4 as a potential vaccine candidate and substitute for ESAT-6. We have now examined the vaccine potential of this protein and found that vaccination with TB10.4 induced a significant protection against tuberculosis. Fusing Ag85B to TB10.4 produced an even more effective vaccine, which induced protection against tuberculosis comparable to bacillus Calmette-Guérin vaccination and superior to the individual Ag components. Thus, Ag85B-TB10 represents a new promising vaccine candidate against tuberculosis. Furthermore, having now exchanged ESAT-6 for TB10.4, we show that ESAT-6, apart from being an excellent diagnostic reagent, can also be used as a reagent for monitoring vaccine efficacy. This may open a new way for monitoring vaccine efficacy in clinical trials.




This article has been cited by other articles:


Home page
 CVIHome page
G. L. Beamer, D. K. Flaherty, B. Vesosky, and J. Turner
Peripheral Blood Gamma Interferon Release Assays Predict Lung Responses and Mycobacterium tuberculosis Disease Outcome in Mice
Clin. Vaccine Immunol., March 1, 2008; 15(3): 474 - 483.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
K. Radosevic, C. W. Wieland, A. Rodriguez, G. J. Weverling, R. Mintardjo, G. Gillissen, R. Vogels, Y. A. W. Skeiky, D. M. Hone, J. C. Sadoff, et al.
Protective Immune Responses to a Recombinant Adenovirus Type 35 Tuberculosis Vaccine in Two Mouse Strains: CD4 and CD8 T-Cell Epitope Mapping and Role of Gamma Interferon
Infect. Immun., August 1, 2007; 75(8): 4105 - 4115.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. X. Rangaka, K. A. Wilkinson, R. Seldon, G. Van Cutsem, G. A. Meintjes, C. Morroni, P. Mouton, L. Diwakar, T. G. Connell, G. Maartens, et al.
Effect of HIV-1 Infection on T-Cell-based and Skin Test Detection of Tuberculosis Infection
Am. J. Respir. Crit. Care Med., March 1, 2007; 175(5): 514 - 520.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
C. S. Andersen, J. Dietrich, E. M. Agger, N. Y. Lycke, K. Lovgren, and P. Andersen
The Combined CTA1-DD/ISCOMs Vector Is an Effective Intranasal Adjuvant for Boosting Prior Mycobacterium bovis BCG Immunity to Mycobacterium tuberculosis
Infect. Immun., January 1, 2007; 75(1): 408 - 416.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
A. S. Mustafa, Y. A. Skeiky, R. Al-Attiyah, M. R. Alderson, R. G. Hewinson, and H. M. Vordermeier
Immunogenicity of Mycobacterium tuberculosis Antigens in Mycobacterium bovis BCG-Vaccinated and M. bovis-Infected Cattle.
Infect. Immun., August 1, 2006; 74(8): 4566 - 4572.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
S. Hervas-Stubbs, L. Majlessi, M. Simsova, J. Morova, M.-J. Rojas, C. Nouze, P. Brodin, P. Sebo, and C. Leclerc
High Frequency of CD4+ T Cells Specific for the TB10.4 Protein Correlates with Protection against Mycobacterium tuberculosis Infection.
Infect. Immun., June 1, 2006; 74(6): 3396 - 3407.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
L. Majlessi, M. Simsova, Z. Jarvis, P. Brodin, M.-J. Rojas, C. Bauche, C. Nouze, D. Ladant, S. T. Cole, P. Sebo, et al.
An Increase in Antimycobacterial Th1-Cell Responses by Prime-Boost Protocols of Immunization Does Not Enhance Protection against Tuberculosis
Infect. Immun., April 1, 2006; 74(4): 2128 - 2137.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
T. M. Doherty and P. Andersen
Vaccines for Tuberculosis: Novel Concepts and Recent Progress
Clin. Microbiol. Rev., October 1, 2005; 18(4): 687 - 702.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.